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Abstract

Apurva Manohar Hegde, B.E.
Advisor: Subrata Sen, Ph.D.

Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in
the US. Among the many genomic aberrations previously implicated in
colorectal cancer, recurrent amplification of chromosome 20q is frequently
associated with liver metastasis. Previous research in our lab identified a
gene signature on chromosome 20q associated with colorectal cancer
progression. In this study, one of the genes in the signature, the ubiquitin
conjugating enzyme UBE2C, was identified through preliminary bioinformatics
analysis as a candidate for further examination of its role in CRC progression.
Co-expression analysis of UBE2C in tumor-normal datasets from the public
database Oncomine revealed all the datasets showing its highest coexpression with Aurora kinase A (AURKA) pathway members, i.e. with
AURKA and its binding co-factor and activator TPX2, all being localized on
chromosome 20q. In addition, preliminary immunoblotting experiments in a
panel of ten CRC cell lines showed high positive correlation between
endogenous protein expression of UBE2C and AURKA. Overexpression of
AURKA led to an increase in UBE2C protein as well as transcript levels,
although UBE2C protein levels remained stable when cells were treated with
Aurora kinase A inhibitor, suggesting that the mechanism of regulation is
independent of the kinase activity. Furthermore, we found evidence of a novel
interaction between AURKA and UBE2C protein by co-immunoprecipitation
experiments. Finally, we assessed the impact of AURKA expression on the
half-life of UBE2C protein using cycloheximide pule-chase assay. In
summary, we report a novel relationship between two cell cycle proteins
AURKA and UBE2C with potential implications for a new combination therapy
in colon cancer.
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Background and Introduction
Cancer is a group of diseases characterized by uncontrolled growth and
spread of abnormal cells, with disruption of the genetic architecture of cells
being one of the hallmarks of the disease. It has emerged as one of the most
dreaded diseases known to mankind and poses a formidable challenge in the
field of medicine. Cancer of the colon and rectum in particular, is estimated to
cause 49,700 deaths in the United States in 2015, the third leading cause of
cancer-related deaths for the two sexes separately, and the second leading
cause when men and women are combined [Cancer Facts & Figures (2015),
Link 1]. Despite increased screening for premalignant lesions contributing to
decreased incidence of this disease over the past 20 years, the rate per
100,000 still remains high in the US, with survival rate dropping from 90% in
patients with localized disease to only 13% in patients with distant metastatic
spread [Global Cancer Facts & Figures (2014), Link 2; Cancer Facts &
Figures (2015)]. Therefore, elucidating the underlying mechanisms driving
progression of this cancer is essential for developing effective biomarkers and
therapeutic interventions.

Colorectal Cancer pathogenesis
Figure 1 shows different pathways known to cause Colorectal Cancers
(CRCs) [1].
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Figure 1. Molecular pathways implicated in colorectal tumorigenesis. The
chromosomal instability pathway characterized by sequential loss-of-function
and gain-of-function aberrations in tumor suppressors and oncogenes
respectively, was first discovered, followed by microsatellite instability
pathway that affects DNA mismatch-repair genes. Recently, another pathway
that is characterized by epigenetic changes to key mismatch repair genes has
been discovered in a smaller set of patients.
Reprinted by permission from Macmillan Publishers Ltd: American
Gastroenterology (Ahnen, DJ; 2011; 106(2):190-8), copyright (2011).
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CRCs are diverse in their underlying genetic makeup and are frequently
characterized by genetic instability [2], arising due to microsatellite instability
(MIN) and

chromosomal instability (CIN). These two pathways of CRC

pathogenesis are thought to evolve independently. MSI tumors make up
about 15% of all CRCs, harboring mutations, mismatched basepairs and/or
indels in the repetitive microsatellite sequences present throughout the human
genome [3]. These characteristic alterations in the microsatellite sequences
have been shown to arise due to defects in DNA mismatch repair genes [4].
The rest of the ~85% of CRCs are characterized by CIN, which is reflected in
persistent gain or loss of whole chromosomes or large portions of
chromosomes [5].
Although whether CIN is the cause or consequence of tumorigenesis is
still debated [6, 7], it is beyond doubt that CIN increases the likelihood of
tumorigenesis and drives the progression of the disease. Multiple studies,
including a meta-analysis of ~10,000 patients by Walther et al in 2008, have
shown CIN to be significantly associated with a worse prognosis and survival
in CRC patients [8-10]. Another study found CIN to confer intrinsic multidrug
resistance to colorectal tumors [9]. Though the importance of CIN has been
well studied in the context of various cancer types, the molecular mechanisms
driving the genomic changes that are characteristic of CIN are not yet fully
understood.
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Chromosome 20q in CRC pathogenesis
One genomic aberration that is frequently seen in CIN tumors is gain of
chromosome arm 20q. Chromosome 20q is one of the most frequently
amplified genomic regions in colorectal tumors [11, 12] and is reported to
occur early during tumorigenesis [13, 14]. In 2011, Tabach et al proposed a
model of cancer initiation driven by spontaneous 20q amplification, describing
the upregulation of expression of genes localized on 20q directly and
indirectly altering the role of transcription factors as well as oncogenic
signaling pathways, thus causing a change in various cellular functions
including cell cycle activity, metabolic pathways and cell-adhesion.

This

finding was confirmed by the large scale study undertaken by The Cancer
Genome Atlas (TCGA) consortium, which identified chromosome 20q13.12 as
one of the genomic hotspots associated with tumor aggressiveness [15].
Specifically, several studies have found amplifications on chromosome
20q to be associated with liver metastasis [16-22], one of the predominant
sites of metastasis in colorectal cancer [23] . In 2000, Hidaka et al showed
that primary CRC tumors with liver metastasis are enriched for amplification in
regions of chromosome 20q, with at least 89% of primary tumors with liver
metastases and 94% of metastatic lesions showing gains on chromosome
20q and the mean level of relative copy number correlating with tumor
progression [19]. More recently, the application of newer technology to study
chromosome 20q amplifications have confirmed these findings. In 2010,
Sayague´s, J.M. et al utilized data from 500K SNP arrays to confirm that the
genetic profile of metastatic CRC was defined by imbalanced gains of
chromosomal regions that frequently included chromosome 20q [11]. In the
4

same year, Bruin S.C. et al described a novel classifier system named LMPAM predominantly based on chromosome 20q aberrations, to predict
patients who were likely to develop liver metastasis with an accuracy rate of
80% [17]. Evidence from such studies suggests that genes on chromosome
20q likely drive the selection for the amplification of this region of the genome
in more aggressive tumors.
Previous work in our lab identified a chromosome 20q gene signature
associated with CRC progression [Carter, J. et al, unpublished data], by
utilizing two in vitro colorectal cancer model systems – the SW (SW480 and
SW620) and KM12 (KM12C, KM12SM and KM12L4C) series cell lines. The
cell line SW480 was derived from the primary colon tumor of a Duke’s Stage
B CRC patient whereas SW680 is the lymph-node derivative of the same
patient with recurrent metastatic disease [24]. In contrast, the highly
metastatic KM12SM and KM12L4C cell lines were established from tumors
growing in nude mice that had been implanted with KM12C cells, the poorly
metastatic parental line derived from a Duke’s Stage B colorectal tumor, into
the spleen of nude mice or injecting subcutaneously into their cecum [25].
Integrated copy number and mRNA expression analysis of the five cell lines
led to the identification of a 4-gene signature localized on the three Minimal
Common Regions (MCRs) of amplification on chromosome 20q, suggesting
that these amplified genomic regions containing the gene signature are
selected for during the metastatic process.
The gene signature consists of 4 genes, namely BMP7, DNMT3B, UBE2C
and YWHAB, all of which have been previously implicated in cancer [26-34].
Moreover, when the gene signature was analyzed in a large cohort of patients
5

from The Cancer Genome Atlas Colorectal Cancer study, the expression
profile of the gene signature was found to show significant association with
negative prognostic characteristics like lymph node spread and/or distant
metastasis, as well as CIN expression subtype, suggesting that gain of
function alterations in the gene signature may contribute to disease
progression.

Investigation of candidate gene for further examination
The rationale behind this study was to narrow down on one candidate
gene from the signature whose functional impact on the progression of CRC
could be studied at a molecular level. We used two filtering criteria to prioritize
the genes of the 20q signature for further examination. The first criteria
included the results of a recent study by Zhang et al in 2014, characterizing
the proteogenomic profile of the colorectal sample cohort from the TCGA
dataset. This was the first large scale study to integrate the genotype and
phenotype information based on proteomic and genomic profiles in CRCs
[35]. In this study, the proteomic analysis of 95 CRC samples, performed
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and
covering a total of 7,211 genes, was compared to the corresponding genomic
aberrations as well as RNA-seq information reported in the original CRC
samples analyzed by TCGA. The findings show that chromosome 20q gain is
associated with the largest global mRNA and protein level changes in CRC.
89% of the 79 genes that had quantifiable protein measurements showed
significant Copy Number Alteration (CNA)-mRNA correlation, but only 51%
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showed significant CNA-protein correlation (P<0.01), suggesting that these
genes may be preferentially selected for during the tumorigenic process. In
particular, of the four genes in the gene signature, it was interesting to note
that UBE2C and YWHAB showed significant CNA-mRNA as well as CNAprotein correlation, indicating that these genes may have a direct functional
impact on tumorigenesis. It must be noted that the other two genes in the
signature – BMP7 and DNMT3B, did not have quantifiable protein
measurements that could be utilized for this analysis. Nevertheless, this
finding helped narrow down from four to two candidate genes for further
examination in our study.
Secondly, we wanted to examine if the candidate genes revealed a
pattern of co-expression with previously well-characterized oncogenes. We
performed co-expression analysis in silico using the public database
Oncomine on ten colorectal tumor datasets where we examined genes that
co-expressed with UBE2C and YWHAB. While YWHAB did not show a
discernible pattern of significant co-expression with any particular cancerrelated signaling pathway across the datasets, UBE2C was highly coexpressed with the Aurora A Kinase (AURKA) pathway members, i.e. AURKA
and its binding and activating co-factor TPX2, in ten out of ten datasets,
suggesting a pattern of co-expression of UBE2C with known cancer driver
genes. A representative result is in Figure 2, data used from Tsukamoto et al,
2011[36].
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Figure 2. Co-expression analysis of mRNA expression data from Oncomine.
Example dataset shown is from Tsukamoto et al, Clin Cancer Research
(2011) [36]. Correlation of expression of UBE2C and AURKA at the mRNA
level is evident across the normal samples and different tumor types, with the
expression increasing in carcinomas, compared to adenomas and normal
samples.
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Similarly, when we analyzed the mutual co-occurrence of overexpression of
UBE2C and YWHAB with AURKA in the TCGA CRC cohort, UBE2C and
AURKA revealed a higher mutual co-occurrence rate as compared to YWHAB
and AURKA (Figure 3). This further confirmed the co-expression analysis
results from Oncomine.

Figure 3. Mutual exclusivity analysis from cBioPortal website. Overexpression
of UBE2C and AURKA shows a stronger tendency of co-occurrence at the
mRNA level as compared to that between AURKA and YWHAB. Analysis was
performed using TCGA Colorectal Cancer study samples (as of August 2014).
Legend is provided for the color scheme represented.
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Since the Oncomine co-expression analysis was performed using mRNA
expression data, we wanted to validate these findings at the protein level. A
preliminary examination of endogenous protein levels of AURKA and UBE2C
by western blotting in ten exponentially growing colorectal cancer cell lines
revealed that six of the ten cell lines showed a positive correlation between
AURKA and UBE2C protein expression, whereas we did not see any
correlation between AURKA and YWHAB, as the expression of YWHAB was
unchanged in all cell lines.
Given that AURKA and TPX2 have been previously reported to promote
20q-amplicon-driven colorectal adenoma to carcinoma progression [37], it
was interesting to note that UBE2C expression was positively correlated with
AURKA pathway members at the mRNA and protein levels, suggesting a
possible co-operation between the signaling axes in driving tumorigenesis,
thus prompting us to further focus on the possible interaction between the
two, to investigate their potential impact on CRC pathogenesis.
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Hypothesis and aims of the project

Based on the aforementioned observations, the central hypothesis of this
project is that functional interaction between AURKA and UBE2C contributes
to colorectal carcinogenesis.
To test this hypothesis, I propose the following specific aims
1)

AIM 1: To determine the effect of change in AURKA protein
expression and activity on UBE2C protein levels

2)

AIM 2: To examine the effect of change in AURKA expression on
the transcriptional regulation of UBE2C expression.
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Methods
Cell lines and tissue culture
A total of ten cell lines were used in this study. Caco-2, SW480, SW620,
HT-29, HCT116, RKO and DLD-1 were procured from American Type Culture
Collection (ATCC). The KM12 series of cell lines were a gift from Dr Isaiah
Fidler’s laboratory at UT MD Anderson Cancer Center. Caco-2, HCT116 and
RKO cell lines were cultured in MEM media, HT-29 in McCoy’s media, DLD-1
in RPMI-1640 and SW series of cell lines in DMEM/high glucose media, all
with 10% FBS (15% FBS for Caco-2), 1% L-glutamine and 1%
Penicillin/Streptomycin (Corning, 25-005-Cl and 30-002-Cl respectively);
KM12 series of cell lines were cultured in MEM media with 1mM sodium
pyruvate (Sigma-Aldrich, S8636), 1ml of NEAA per 100ml of media (Lonza,
13-114E), 1% L-glutamine and 1% Penicillin/Streptomycin. All cells were
cultured in a CO2 incubator with 5% CO2 at 37oC.

Transfection of DNA, siRNA and Protein isolation
5ug plasmid DNA and 80nm SiRNA were transfected into cells in serum free
media at 70-80% confluence using OPTIMEM reduced serum reagent (Life
technologies

Inc)

and

Lipofectamine

2000

(Life

Technologies

Inc.)

transfection reagent, according to manufacturer’s recommendation, for 24 to
72 hours. Media was changed to normal growth media 6 hours after
transfection.

SiRNA

targeting

AURKA

(custom

SiRNA

sequence

AUGCCCUGUCUUACUGUCA) and UBE2C (SMARTpool ON-TARGET plus,
catalog no. LU-004693-00-0005) were procured from GE Dharmacon. To
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isolate protein, cells were washed twice with 100% PBS and lysed with 0.1L
buffer (for 50ml buffer: 0.02M Tris HCl (pH 8.0), 0.1M NaCl, 500uM EDTA,
0.05M NaF, 1% NP40, Protease inhibitor (Roche) – 1 tablet, make up the
volume to 50ml with ddH20) for co-IP and RIPA buffer (for 50ml buffer: 0.02M
Tris-HCl, 0.15M NaCl, 1uM EDTA, 1% Triton X-100, 0.5% Sodium
Deoxycholate, 0.1% SDS, protease inhibitor – 1 tablet, make up the volume to
50ml with ddH20). Protein concentration was measured using Bradford
reagent (Bio-Rad) according to manufacturer’s protocol.

Drug treatments
Alisertib (MLN8237) was dissolved in 100% DMSO and was used at
100nM and 500nM concentration for 1 hour and 24 hours. Corresponding
volumes of 0.05% DMSO treatment was used as negative control. Total
protein was isolated from lysed cells as described above. For co-IP
experiments with cells arrested in mitosis, nocodazole treatment was
performed at 2.5ug/ml concentration for 16 hours.

Quantitative Real Time PCR
Total RNA was isolated from transfected cells using TRIzol reagent
(Invitrogen) and phenol-chloroform precipitation according to manufacturer’s
recommendation. Extracted RNA was treated with DNase I (Life technologies)
to remove DNA contamination. 2-3 ug DNase-treated RNA was converted to
cDNA using Superscript II RT kit (Life Technologies) according to
manufacturer’s recommended protocol. Primer sequences are: AURKA Fwd 13

5’-GCCCTGTCTTACTGTCATTCG-3”,

Rev
UBE2C

ACAGAGAGTGGTCCTCCTGG-3’,

–
Fwd

5’–

5’-

GGACCATTCTGCTCTCCATCC-3’, Rev – 5’- AGCTGTGGGGTTTTTCCAG 3’. mRNA levels were quantified using SYBR green qPCR master mix (Life
technologies, catalog no. 4309155) and fluorescent signal was measured by a
ViiA 7 Real-Time PCR System (Life technologies). Target specificity was
confirmed by melting curve analysis. Relative gene expression fold change
values were calculated using the 2-ΔΔCTmethod as outlined in Link 3. Variance
in the normalized RT-PCR values was calculated using the F-test and
statistical significance was calculated using the Student’s t-test. Graphs were
created using Graphpad prism.

Co-immunoprecipitation
1mg of protein was pre-cleared by incubation with protein-A agarose
beads while rotating for 1 hour at 4oC. The supernatant was incubated with
primary antibody overnight at 4oC. The antibody-protein lysate mixture was
then incubated with fresh protein-A agarose beads and the unbound
supernatant was discarded. The beads were denatured using SDS and heat
denaturation by boiling for 5 minutes. These samples were then used to
perform SDS PAGE followed by western blotting as described below.

Cycloheximide assay
Cells were cultured in 10 cm dishes and transfected either with Flag-tagged
AURKA and empty vectors for a period of 24 hours, or siAURKA and
14

scrambled siRNA for 48 hours, using lipofectamine2000 transfection reagent,
using manufacturer’s protocol. Cycloheximide reagent at a concentration of
50ug/ml was added to the cells and cells were harvested with RIPA at various
time points. Immunoblotting was carried out after protein isolation and
quantification as described above and below.

Immunoblotting
Cell lysates or co-IP samples as stated above, were denatured using 1X
SDS and by boiling at 100oC for 5 minutes. Denatured cell lysates were run
on either 10% or 12% polyacrylamide gels, transferred to nitrocellulose
membrane, and incubated with primary antibody (List of primary and
secondary antibodies in Table 1) on a shaker at 4oC, overnight.
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Antibody

Company (Catalog no).

IAK

BD (610939)

BTAK/STK15

[38]

UBE2C (full length)

Abcam (ab56861)

UBE2C (N-terminal)

Abgent (AP2119a)

UBE2C (C-terminal)

Abgent (AP2119b)

Phospho-AURK A/B/C

YWHAB

CST (29146)
Bethyl laboratories (A310101A)
Santa Cruz (SC-629)

BMP-7

Sant Cruz (SC-9305)

ID1

Santa Cruz (SC-488)

Flag

Sigma (F1804)

Cleaved PARP

CST (9541S)

Cleaved Caspase

CST (9661)

HSP90

Santa Cruz (SC-13119)

ACTB

Santa Cruz (47778)

Anti-HRP (Rabbit IgG)

Genedepot (W3902-500)

Anti-HRP (Mouse IgG)

GE Healthcare (NXA931)

TPX2

Table 1. List of antibodies used in western blotting.
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Results

AURKA and UBE2C protein expression are positively correlated in colon
cancer cells
In order to validate the results of the Oncomine co-expression analysis as
well as our findings from the TCGA mutual-co-occurrence analysis in
colorectal cancer, we examined the endogenous protein levels of AURKA and
UBE2C in ten cell lines by western blotting. These were seven MSS cell lines
including Caco2, SW480, SW620, KM12C, KM12SM, KM12L4A, HT-29 and
three MSI cell lines including HCT116, RKO and DLD-1. We observed a
positive correlation between AURKA and UBE2C in six of the ten cell lines
(Figure 4). Those cell lines that showed higher endogenous AURKA protein
levels also showed high UBE2C expression, cell lines with moderate AURKA
expression revealed relatively lower UBE2C levels whereas the cell lines that
expressed very little AURKA protein showed the lowest UBE2C levels. In
addition, we observed a similar phenomenon with the expression of TPX2, the
binding and activating partner of AURKA, showing positive correlation with
AURKA and UBE2C. We also examined the expression levels of ID1 and
BMP-7 which are localized on chromosome 20q, to confirm that the
correlation did not stem due to potential amplification of chromosome 20q,
and did not see a correlation of their expression with AURKA.
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Figure 4. Endogenous expression of UBE2C, AURKA, phospho-AURKA and
additional chromosome 20q encoded proteins (YWHAB, TPX2, ID1, BMP-7).
Cell lines that show highest AURKA expression also show high expression of
UBE2C whereas cell lines with low AURKA expression also express UBE2C
at very low levels. Loading control used is HSP90.
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AURKA overexpression leads to increase in UBE2C protein levels
We were interested in examining whether change in AURKA expression
would effect a change in UBE2C levels too. Three cell lines were chosen for
further examination based on their endogenous expression levels of AURKA
and UBE2C, their comparable doubling time as well as transfection efficiency,
with one cell line, SW480, being consistently used in all experiments.
Overexpression of Flag-tagged AURKA by transient transfection led to an
increase of UBE2C protein levels as compared to empty vector controls in all
three cell lines, indicating a positive correlation between the expression levels
of the two proteins (Figure 5). As can be seen from the figure, we confirmed
transfection efficiency by checking the intensity of the Flag epitope in the
expressed Flag-tagged AURKA protein.
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Figure 5. Protein expression of UBE2C when Flag-tagged AURKA plasmids
are transiently transfected into SW480, KM12C and HT-29 cells, as
determined by immunoblotting. Expression of UBE2C increases when AURKA
is overexpressed.
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AURKA knockdown down-regulates UBE2C expression at the protein
level
We wanted to confirm the above findings to see whether UBE2C levels
decrease upon knockdown of AURKA expression. We treated three cell lines,
SW480, KM12C and HT-29, with siRNA targeting AURKA and probed for
UBE2C protein using western blotting. siRNA sequences for AURKA are
provided in the Methods section. We observed a corresponding decrease in
UBE2C expression when AURKA expression was down-regulated, confirming
the above observation that a positive correlation exists between AURKA and
UBE2C in colon cancer cells (Figure 6) and suggesting that AURKA regulates
UBE2C expression either transcriptionally or post-translationally.
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Figure 6. Protein expression of UBE2C when AURKA is knocked down by
siRNA treatment in SW480, KM12C and HT-29 cells, as determined by
immunoblotting. Expression of UBE2C also decreases when AURKA levels
are diminished.
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Positive correlation between AURKA and UBE2C expression is reflected
at the mRNA level
We were curious to see whether the above phenomenon was limited to
the protein level, thus indicating a solely post-translational mechanism of
regulation of UBE2C expression, or whether it was also reflected at the
transcript levels. We overexpressed Flag-tagged AURKA in SW480 and
KM12C cell lines and checked for the expression of AURKA and UBE2C
mRNAs using quantitative RT-PCR. Primer sequences for the PCR assay can
be found in the Methods section. We observed a statistically significant
increase in the expression of UBE2C mRNA in the presence of higher
expression of AURKA (Figure 7).

Figure 7. mRNA expression of UBE2C when Flag-tagged AURKA is
overexpressed, as determined by quantitative RT-PCR (* p<0.01, ** p=0.02).
Overexpression of AURKA leads to a moderate increase in UBE2C levels.

23

We further wanted to confirm these results by investigating the effect of
knockdown of AURKA on UBE2C mRNA levels. RNAi-mediated downregulation of AURKA led to a statistically significant decrease in UBE2C
transcript levels, as seen in Figure 8.

Figure 8. mRNA expression of UBE2C when AURKA is knocked down by
siRNA treatment, as determined by quantitative RT-PCR (* p<0.01, ***
p<0.05). Knock-down of AURKA leads to a moderate decrease of UBE2C.

The above results suggested the possibility that AURKA may be
involved in transcriptional regulation of UBE2C expression. Searching for
potential DNA-binding or transactivation sites in the AURKA protein sequence
using multiple prediction softwares did not yield any predicted sites. We were
also curious to see whether known targets of AURKA may be acting as
potential transcription factors and helping regulate UBE2C levels. However,
potential transcription factor binding sites in the UBE2C promoter region from
ENCODE did not reveal any known AURKA downstream targets in the list of
most relevant predicted transcription factor binding sites (Link 4). The
findings, nonetheless, raise the interesting possibility that transcription
factor(s) regulating UBE2C expression may be substrate(s) of AURKA, which
remain to be identified. Besides, AURKA appears to be regulating UBE2C
protein expression at the translational level.
24

Regulation of UBE2C expression is independent of AURKA kinase
activity
Since Aurora A functions primarily as a serine/threonine kinase, we
wanted to examine the change in UBE2C expression when kinase activity of
AURKA was inhibited using the drug Alisertib (MLN8237). We treated the cell
lines SW480 and KM12C with increasing doses of the drug, each for 1 hour
and 24 hour durations, inducing the repression of phospho-AURKA
expression. As seen in Figure 9, we did not see a change in UBE2C levels
between treated and untreated controls at 100nM concentration of the drug,
though at the 500nM concentration of Alisertib treatment, we did see a
decrease in the protein levels of UBE2C. However, at this concentration we
also saw decrease in activated AURKB and AURKC. Since it is known that
Alisertib shows >200 fold higher selectivity for AURKA over the other Aurora
kinases [39], it leads us to believe that the change in UBE2C may be due to
off-target effects of the drug and may not truly reflect the change caused by
inhibition of AURKA alone.
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Figure 9. Protein expression of UBE2C after treatment of SW480 (a) and
KM12C (b) cell lines with AURKA inhibitor Alisertib, as determined by
immunoblotting. Decrease of activated AURKA does not show significant
change in UBE2C protein expression.
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Co-immunoprecipitation shows evidence of binding between UBE2C
and AURKA
Keeping in view the recent study showing kinase-independent regulatory
function of AURKA in neuroblastoma cells [40], we sought to examine
whether AURKA may be binding to UBE2C in the cell and thus playing a role
in increasing its expression. On performing co-immunoprecipitation of AURKA
and UBE2C in exponentially growing SW480 and KM12C cells, we observed
UBE2C binding to AURKA (Figure 10 a). Interestingly, in both cell lines we
were able to visualize the binding only when UBE2C antibody was used for
immunoprecipitation and AURKA was probed in the immunecomplex by
immunoblotting. However, we failed to detect UBE2C protein in immunecomplex precipitated with AURKA antibody. .
AURKA is a mitosis regulatory enzyme that peaks expression during G2-M
phase of mitosis. In order to rule out the possibility that low expression of
AURKA in exponentially growing cells limits its availability for binding with
UBE2C, we treated SW480 cells with nocodazole, which is an anti-neoplastic
agent that arrests cells in mitosis by inhibiting microtubule polymerization.
This time, we did detect UBE2C binding to immunoprecipitated AURKA,
although the interaction was weak (Figure 10 b).
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a.

b.

Figure 10. Co-immunoprecipitation of AURKA and UBE2C in a) exponentially
growing SW480 and KM12C cells and b) Nocodazole treated SW480 cells.
AURKA binding is visible in samples where UBE2C has been
immunoprecipitated and probed for the presence of AURKA.
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UBE2C protein levels are stabilized by AURKA expression
As shown above, the results of the AURKA-overexpression and
knockdown studies indicated a correlation in the expression of AURKA and
UBE2C. In addition, we also found AURKA binding to UBE2C, suggesting the
possibility that AURKA may be involved in stabilization of UBE2C levels in the
cell. We performed cycloheximide pulse-chase assay to determine the effect
of change in AURKA expression on half-life of UBE2C. Cycloheximide
treatment was performed on SW480 cells that had undergone AURKA
overexpression for 24 hours as compared to empty vector controls, following
which cells were harvested at various time points to examine the levels of
protein expression. Conversely, we also studied cells in which AURKA had
been knocked down for 48 hours using RNAi and compared them to cells
expressing scrambled Si controls for protein expression levels in the presence
of cycloheximide.
In the first case, we found that UBE2C as well as AURKA expression in
empty-vector treated cells was diminished at the 4 hour time point , whereas
cells that showed overexpression of AURKA also showed higher expression
of UBE2C at this time interval, with expression returning to basal levels after
decrease in AURKA expression at 10 hours (Figure 11 a). In contrast, in cells
where AURKA had been knocked down using siRNA, UBE2C levels
diminished at the 6 hour time point, whereas scrambled Si transfected cells
showing higher AURKA levels did not show diminished UBE2C expression,
although its expression did change in correlation with that of AURKA (Figure
11 b). These results indicate that AURKA protein level is involved in regulating
the protein half-life of UBE2C.
29

a.
SW480

b.
SW480

Figure 11. AURKA and UBE2C expression as determined by densitometrybased quantification of immunoblot signals performed after cycloheximide
pulse-chase assay in SW480 cells. Higher AURKA expression shows higher
levels of UBE2C for longer intervals of time.
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Summary and Discussion
The focus of this work was to explore a possible novel interaction between
cell cycle enzymes Aurora A Kinase (AURKA) and ubiquitin conjugating
enzyme E2C (UBE2C) in colon cancer cells, both encoded on chromosome
20q and displaying similar elevated expression profiles in large colon cancer
sample cohorts reported in publicly available datasets, such as, Oncomine
and TCGA. . Implication of chromosome 20q amplification in colorectal cancer
progression has been well documented, but attempts at narrowing down the
genes that drive the selection for this amplification seen in CRCs, especially in
tumors that metastasize to the liver have so far been limited. The significance
of this study lies in the possibility that disruption of this plausible interaction
may help in developing new therapeutic strategies for CRC patients who
overexpress these proteins.
The Aurora kinase gene was first discovered in Drosophila melanogaster
as being responsible for the formation of defective, monopolar spindles when
mutated [41]. Since then, three homologous proteins of the kinase family have
been discovered in humans – Aurora A, B and C kinases (AURKA, AURKB,
AURKC). AURKA has been well studied as a cell cycle enzyme that
predominantly localizes at the centrosomes during mitosis and at the spindle
poles through to the M phase of the cell cycle, regulating important functions
like centrosome maturation, microtubule formation and spindle assembly [42].
The association of AURKA with cancer was first reported two years after
the gene was discovered. In 1997, Sen et al was the first group to report
AURKA (BTAK) as amplified and overexpressed in breast cancer cells [43].
Since then elevated levels of AURKA have been reported in multiple cancers,
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including almost 94% of invasive ductal carcinoma of the breast showing
enhanced expression of AURKA [43] and it’s overexpression was shown to
cause tumorigenic transformation both in vitro and in vivo [38, 44].
Chromosome 20q13.2, the region that AURKA maps to, is a known
hotspot for amplification in many human cancers. Owing to its function as a
cell cycle regulatory protein, amplification and overexpression of AURKA has
important implications for deregulation of normal cellular growth. Elevated
levels of AURKA aid in overriding the spindle checkpoint that is activated
when cells are treated with chemotherapeutic agents causing defective
spindle assembly as well as microtubule destabilization [45, 46]. Moreover,
AURKA overexpression leads to centrosome amplification resulting in
defective chromosome segregation and failure of cytokinesis, thus giving rise
to aneuploidy [38] and contributing to carcinogenesis.
Other molecular mechanisms through which AURKA contributes to
disease progression have also come to light. In 2004, Katayama et al reported
that increased AURKA expression leads to the phosphorylation and
subsequent Mdm2-mediated degradation of p53, thus shutting down an
important tumor suppressive pathway in cancer cells [47]. In the same year, it
was also reported that AURKA-mediated phosphorylation of p53 at Ser215
abrogates p53’s DNA-binding and transactivation functions, thus leading to
downregulation of the downstream tumor suppressor transcriptional targets of
p53 like p21 and PTEN [48]. In addition to the degradation of p53, AURKA
also circumvents the p53-mediated apoptotic pathway by the suppression of
p73 [49, 50].
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Given these important findings suggesting involvement of AURKA in
carcinogenesis, it is apparent that AURKA is a potential therapeutic target for
cancer. Different AURKA inhibitors have been developed, including MLN8054,
which was terminated in phase I clinical trials as off target toxicities were
reported [51]. More selective second generation drug MLN8237 (Alisertib),
has shown improved efficacy in causing tumor regression by induction of
senescence on the one hand and activation of apoptotic pathways on the
other [52, 53] . It is currently in clinical trials for some solid tumors both as a
single agent as well as in combination with other drugs; however in recent
clinical trials in gastrointestinal tumors, a small percentage of patients have
shown a partial response to the drug [54]. Stratification of patients based on
other biomarkers and combination therapy of AURKA inhibitors with other
therapies is expected to yield better response among patients.
The ubiquitin conjugating enzyme E2C (UBE2C) gene was first cloned by
Townsley et al in 1997, as a human homolog of the E2C ubiquitin carrier
protein found in yeast [55]. The UBE2C gene is located on chromosome
20q13.12 and is reported to have seven transcript variants generated through
alternative splicing. UBE2C forms an important component of a large multisubunit

ubiquitin

ligase

complex

called

the

Anaphase

Promoting

Complex/Cyclosome (APC/C), which is required to ensure timely degradation
of cell cycle molecules like Securin and Cyclin B1 in order for the cell to
transition from metaphase to anaphase [56]. Specifically, it is involved in the
initiation of mono- and poly-ubiquitination of APC/C targets within the cell [57,
58]. It further promotes the ubiquitination of mitotic checkpoint proteins,
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therefore helping in the inactivation of the spindle checkpoint allowing
chromosome segregation to occur [59].
Perhaps due to its important functions in cell cycle progression, elevated
levels of UBE2C have been observed in various cancers, including colon,
liver, bladder, lung, gastric, breast, ovarian, etc. [60-63]. Its high expression
has been associated with poor survival in lung cancer, high risk breast cancer
patients, ovarian cancer, etc. [64-67]. In vitro, UBE2C overexpression was
shown to impair mitotic arrest in cancer cells in the presence of spindle
damaging agents like nocodazole [68], while in vivo, overexpression of
UBE2C led to chromosome missegregation and aneuploidy due to increased
APC/C activity [31]. It had also been shown earlier that when primary oral
Squamous Cell Carcinomas (SCCs) were immortalized in culture, there was a
dramatic increase in UBE2C protein levels [69], suggesting that UBE2C
overexpression may play a role in evasion of senescence and increased cell
proliferation.
More recently, in 2011, Bavi et al demonstrated that RNAi-mediated
knockdown of UBE2C in colon cancer cells led to a decrease in cell growth
[70]. They also observed downregulation of UBE2C on treatment with
proteasome inhibitor Bortezomib, which further sensitized the cells to
Bortezomib- and oxaliplatin-mediated apoptosis, implying that inhibition of
UBE2C leads to suppression of cell growth in vitro. This was confirmed using
xenograft models where Bortezomib-mediated downregulation of UBE2C led
to increased shrinkage in tumor volumes in mice treated with Bortezomib and
Oxaliplatin combination therapy. These observations suggest UBE2C to be a
promising potential therapeutic target in colon cancer.
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In view of the above observations, our data point towards an interesting
possibility of a yet unknown novel functional interaction between AURKA and
UBE2C proteins that are known oncogenes. The mRNA data from TCGA and
Oncomine revealing that overexpression of AURKA and UBE2C are closely
tied was confirmed by our observation of a similar phenomenon at the protein
level in exponentially growing CRC cells. The absence of correlation of
expression of other 20q genes indicates that this phenomenon may not solely
be due to overall 20q gain but more selective to AURKA and UBE2C.
Interestingly, we found that UBE2C expression level is upregulated with
increase in AURKA levels and is downregulated when AURKA is knocked
down, both at the protein as well as mRNA levels. This reveals the possibility
of a novel signaling axis that may be promoting disease progression in a
subset of CRC patients who show overexpression of the two genes.
The absence of predicted DNA-binding and transactivation sites on
AURKA as well as transcription-factor binding sites on UBE2C, coupled with
the limited increase in UBE2C transcript levels even after 25 to 140-fold
increase in AURKA levels indicates that perhaps a more potent posttranslational mechanism of regulation of UBE2C may be occurring in the cells.
In this context, the 2009 study by Otto et al, that found AURKA to stabilize NMYC in a kinase-independent manner in neuroblastoma cells by binding to it
and protecting it from proteasome-mediated degradation becomes relevant
[40]. Our observation that UBE2C levels remain constant in spite of AURKA
inhibition by the drug Alisertib led us to investigate a potential kinaseindependent

mechanism

of

AURKA-mediated

UBE2C

regulation.

Interestingly, in the co-IP studies, we found AURKA binding after
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imunoprecipitating UBE2C from the cell extracts, although failed to detect
UBE2C in the immune complex when we pulled down with AURKA antibody
in both the cell lines. The absence or very low binding of UBE2C detected in
the immune complexes pulled down with AURKA antibody even after
treatment with a mitotic-arrest agent implies that this phenomenon may not be
dependent on the level of expression of AURKA, since AURKA shows highest
expression during mitosis. This may indicate the possibility of preferential
binding of AURKA with other proteins in the cell or the IP antibody competing
with UBE2C to bind to AURKA, which warrants further experiments with
antibodies against various different epitopes on AURKA protein.
Further, the evidence of binding between the two proteins prompted us to
examine whether AURKA may play a role in stabilizing UBE2C levels in the
cell. Cycloheximide assay shows higher levels of UBE2C when AURKA is
expressed in high amounts, with both AURKA and UBE2C expression
decreasing coordinately after several hours of cycloheximide treatment,
indicating protein degradation. In both the samples, protein expression
decreased in parallel at the 4 hour time point but rose again, suggesting that
the cycloheximide may have been metabolized by the cells by this time point.
The overall higher amounts of UBE2C in the scrambled Si-treated cells shows
that it would take longer for it to be degraded in the presence of AURKA
expression as compared to when AURKA levels are knocked down. Taken
together, these studies are suggestive of the positive impact of AURKA
signaling on the expression of UBE2C. However, it would have to be further
determined whether AURKA regulates UBE2C stabilization directly by binding
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to it, by repeating these experiments using deletion and mutation constructs of
UBE2C and AURKA.
In addition, the novel relationship between UBE2C and AURKA
highlighted in this study has the potential to impact different cellular processes
regulated by UBE2C. As mentioned earlier, UBE2C is involved in the initiation
of mono- and poly-ubiquitination of APC/Cyclosome targets within the cell.
While mono-ubiquitination has been reported to play a role in different
processes, including epigenetic regulation of gene expression as well as
modification of proteins that regulate DNA repair pathways, poly-ubiquitination
is generally employed by the cell to target proteins for proteasomal
degradation [71-74]. Overexpression of UBE2C has been reported to cause
cancer cells to enter mitosis even in the presence of spindle damaging agents
like nocodazole [59]. AURKA-mediated overexpression of UBE2C could
potentially have an additive effect on the oncogenic characteristics displayed
when AURKA is overexpressed, by facilitating the deregulation of additional
cellular processes that may be tumor suppressive in nature. This augmented
effect could result in cancer cells exhibiting additional hallmarks of cancer,
thus resulting in more aggressive tumors. Further work to delineate the effects
of AURKA-mediated UBE2C overexpression on potential change in
ubiquitination of its downstream targets will lay the foundation for discerning
whether these changes impact the progression of disease.
In summary, we have successfully uncovered a novel interaction occurring
between the cell cycle enzymes AURKA and UBE2C in colorectal cancer
cells. We have confirmed the correlation of expression of the two proteins as
well as potential regulation of UBE2C by AURKA that may have important
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implications in promoting the aggressiveness of colorectal cancers, in view
the well-characterized oncogenic properties of the proteins. Further
investigation on the effects of abrogation of this interaction as well as
elucidation of other signaling pathways possibly being affected by this
interaction will help determine the importance of therapeutically targeting this
novel signaling axis in CRC patients overexpressing the two proteins.
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Future directions
The demonstrated interaction between AURKA and UBE2C has not been
reported by earlier studies, and therefore has immense potential to be studied
in the context of cancer pathogenesis and aggressiveness of the disease..
The 2009 study by Otto et al elucidating the kinase-independent function
of AURKA in stabilization of N-Myc by binding to it has expanded the diverse
role that AURKA plays in promoting tumorigenesis. Since we have seen the
indication of a similar phenomenon in our studies, it would be helpful to
determine the binding motifs of the two proteins, using first deletion
constructs, then followed by mutation constructs of UBE2C and AURKA to
narrow down on the exact residues involved in this interaction. This will further
help us determine whether binding of the two proteins is crucial in determining
the half-life of UBE2C in the cell or whether increase in UBE2C half-life is
merely the result of activation of AURKA downstream signaling pathway.
The functional impact of the interaction of AURKA and UBE2C on CRC
cells needs to be elucidated. Important cellular functions deregulated in
cancer, like invasive and migratory capacity of cells, could be examined by
wound healing assays as well as other migration-invasion assays using stably
generated cell lines that overexpress both AURKA as well as UBE2C as
compared to cell lines overexpressing UBE2C but low level of AURKA.
Determination of the impact of this signaling axis on the ability of anchorageindependent

growth

and

development of

additional cancer relevant

phenotypes including the role of AURKA in maintaining stemness, as reported
by Lee et al in 2012 [75] will be extremely important in designing effective

39

therapeutic strategies for AURKA and UBE2C over expressing subset of
human cancers.
Crosstalk between the AURKA pathway and important oncogenic
signaling pathways including Wnt/β-catenin has been reported in multiple
myeloma, MYC in neuroblastoma and BMI1 in head and neck cancer [40, 76,
77]. It is likely that interaction between AURKA and UBE2C facilitates and
may even prove to be vital for the activation of other such oncogenic
pathways. An overview of the changes in expression of well-characterized
oncogenes and oncoproteins could be assessed by microarray analysis and
Reverse Phase Protein Array analysis of the cells overexpressing AURKA
and UBE2C as compared to cells with low AURKA expression. Integrating this
data may provide important leads on potential signaling pathways being
affected by the interaction between AURKA and UBE2C.
Although we have observed mutual co-occurrence of overexpression of
AURKA and UBE2C in publicly available datasets at the mRNA level as well
as in cell lines at the protein level, it is important to investigate the
phenomenon in tumor tissues as well. IHC staining of the two proteins in CRC
tissues would not only help validate our observations in the cell lines but also
shed light on the clinical significance of this signaling axis in disease
prognosis and therapeutic response of colorectal cancer patients.
Unlike AURKA which has been the focus of many clinical trials in
hematologic as well as solid tumors, there is as yet no clinical trial targeting
UBE2C, even though its potential as a therapeutic target has been previously
discussed by Bavi et al [70]. This can be first attempted in a pre-clinical
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setting in vitro, by treating cells with a combination of AURKA inhibitor like
Alisertib and proteasome inhibitor like Bortezomib, shown to downregulate
UBE2C, and observing the effects on cell proliferation, migration-invasion, cell
death and chemoresistance, in comparison with these drugs as single agents.
If the results are promising, subsequent pre-clinical in vivo studies with mouse
xenograft models could be undertaken with patient tumors that overexpress
both AURKA and UBE2C to investigate the effect of combination therapy on
tumor response.

Ultimately, stratification of patients based on co-expression

of AURKA and UBE2C could be developed as an important biomarker-based
selection process for administering this combination therapy to patients in
clinical settings. .
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Online Links
Link 1:
http://www.cancer.org/acs/groups/content/@editorial/documents/document/ac
spc-044552.pdf
Link 2:
http://www.cancer.org/acs/groups/content/@research/documents/webcontent/
acspc-042151.pdf
Link 3:
http://dharmacon.gelifesciences.com/uploadedfiles/resources/delta-cq-solaristechnote.pdf
Link 4:
http://genome.ucsc.edu/cgibin/hgTracks?db=hg19&position=chr20%3A4444017044446682&hgsid=429541681_dnRwkuwLu7Ajo61eCv1V3e2oynre
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